We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
EPIX Pharmaceuticals, Inc. announced that its shareholders have voted to approve the Company's merger with Predix Pharmaceuticals Holdings, Inc., which was previously announced on April 3, 2006, as well as each of the other proposals related to the merger.
Rotech Healthcare Inc. reported that on August 10, 2006, it received a warning letter from the Food and Drug Administration (FDA) relating to its subsidiary, Pulmo-Dose, Inc.
Pfizer Inc. said that pharmaceutical division head Karen Katen, who was passed over for CEO last month, will leave the company early next year to pursue other opportunities.
The Federal Trade Commission has extended its antitrust review of Barr Pharmaceuticals Inc.'s proposed tender offer to acquire Pliva d.d., a Croatian generic-drug maker, Barr said.
A federal prescription drug directory fails to list more than 9,000 medications but catalogs tens of thousands more that are no longer on the market, according to a report.
Johnson & Johnson (J&J) subsidiary Alza has sued Wyeth Pharmaceuticals alleging that Wyeth's antidepressant Effexor XR infringes on a J&J patent for technology used to provide controlled release of some drugs, according to court documents filed with the U.S. District Court for the Eastern District of Texas.
The FDA is violating the First Amendment and federal law in establishing de facto limits on DTC advertising through warning letters, the activist group Washington Legal Foundation (WLF) argues.
Sanofi-aventis and Bristol-Myers Squibb (BMS) have asked a U.S. federal court for a preliminary injunction to stop Apotex from selling its generic version of their blockbuster blood thinner Plavix, but a patent agreement they signed with Apotex may prevent them from getting it, according to one legal expert.